Agenda Revealed: STING & TLR Targeting Therapies Summit 2021
Harnessing the activation of innate immunity has become the forefront of new cancer immunotherapies. Only this month SQZ Biotech received FDA clearance for an IND on a cell therapy candidate, transporting tumor-specific antigens and TLR agonists to treat HPV+ tumors.
Enter: STING & TLR-Targeting Therapies Summit!
This May (25-27), 30+ biopharma companies and research institutes will share insight into enabling safe and potent innate immune activation through effective drug administration to target solid tumors and increase response to PD-1/PD-L1 inhibitors.
This is the only industry-led forum dedicated to the development of drug candidates modulating the cGAS-STING and Toll-like receptor (3/7/8/9) pathways both as monotherapies and as adjuvants in combinatorial approaches.
The 2021 agenda has now been revealed – view the event guide here.
30+ Expert Speakers, Including:
- Art Krieg, Founder, Chief Scientific Officer, Checkmate Pharamaceuticals
- Kyriakos Economides, Director, In Vivo Pharmacology, Codiak Biosciences
- Edith Perez, Chief Medical Officer, Bolt Therapeutics
- Robert Andtbacka, Chief Medical Officer, Seven and Eight Biopharmaceuticals
- Laura Glickman, Co-Founder, Vice President Research, Actym Therapeutics
- Joshi Ramanjulu, Senior Director, Head of Project Leader Group & Senior GSK Fellow, Innate Immunity Research Unit, GlaxoSmithKline
They’ll be joining other industry experts from the likes of Boehringer Ingelheim, Decoy Biosystems, Highlight Therapeutics, Mersana Therapeutics, AstraZeneca, UPMC and many more to share insights into increasing patient response rates and the efficacy of checkpoint inhibitors.
View the full speaker list here.
Insights Driven Agenda:
Attendees will gather virtually in May to discuss:
- Improving therapy administration and drug delivery to overcome efficacy and safety challenges
- Advancing the efficacy of your drug candidate in a range of solid tumor indications using the combinatorial approaches
- Guiding selective STING/TLR agonists to specific target sites in solid tumors using ADC, mRNA, Exosome-based and small molecule technologies
- Inducing anti-tumor immunological memory in both the innate and adaptive immune systems to achieve a more consistent immune response
- And more!
Innate Immune Checkpoints & Activation Focus Day:
In addition to two full conference days to STING/TLR-targeting, there will be a pre-focus day specifically on innate immune checkpoints and the activation of specific cell types including natural killer cells, macrophages and myeloid-derived suppressor cells.
An executive speaker faculty will take you through the leading drug candidates aimed at inhibitory and activation receptors on key cellular component of the innate immune system.
Pre-focus day speakers include:
- Arndt Schottelius, Chief Scientific Officer, Affimed
- Nicholas Huntington, Co-Founder & Chief Scientific Officer, oNKo-innate
- Tatiana Novobrantseva, Co-Founder & Chief Scientific Officer, Verseau Therapeutics
- Bob Uger, Chief Scientific Officer, Trillium Therapeutics
- Daniel Getts, Co-Founder & Chief Executive Officer, Myeloid Therapeutics
Click here for the full pre-focus day line-up!
Find Out More:
View the full event guide here for more details about the speakers, agenda, digital platform and pricing.
Alternatively, contact the team using the details below.
And listen out for more updates on the digital STING & TLR-Targeting Therapies Summit!
Contact
General Enquiries & Registration Assistance
Rex Orcajada
Delegate Acquisition Manager
Hanson Wade
(+1) 617 455 4188
info@hansonwade.com
Partnership Opportunities
Jack Marcus
Partnerships Director
Hanson Wade
(+1) 617 455 4188
sponsor@hansonwade.com